Scalper1 News
It’s been an interesting year for drugmaker Acorda Therapeutics. The neurology specialist has been working to diversify from Ampyra, a drug that helps multiple sclerosis patients walk and which provided 90% of Acorda’s (ACOR) revenue in the most recent quarter. Ampyra, launched in 2010, has proved a success in its narrow specialty, with 12-month sales running upward of $300 million. But the drug’s growth has been slowing, and it is already facing Scalper1 News
Scalper1 News